Head and neck cancers (HNCs) are among the most common cancers worldwide.
1 On an annual basis, approximately 65 410 new cases of HNC are diagnosed and nearly 14 620 patients die of HNC in the United States.
2,3 In 2010, the total direct medical cost of HNC in the United States was $3.64 billion.
4 Because of the high prevalence and financial burden associated with HNC, researchers conducting randomized clinical trials (RCTs) addressing HNC should be mindful of any potential research waste. The estimated prevalence of research waste is 85% of all biomedical research, translated to potential waste of $170 billion of the $200 billion spent on research worldwide.
5 Two factors contributing to this financial burden of research waste are studies that never reach publication and studies that are unnecessarily discontinued.